Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MADISON, Wis., Aug. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX Breast Recurrence Score® Program.

Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan

MADISON, Wis., Aug. 13, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that the performance of its Oncoguard™ Liver liquid biopsy test is now published online in the peer-reviewed journal Clinical Gastroenterology and Hepatology (CGH).

Clinical Gastroenterology and Hepatology Publishes Data Showing Exact Sciences' Oncoguard™ Liver Liquid Biopsy Test Delivers Enhanced Performance for Early-stage Detection of Hepatocellular Carcinoma

Invitae

EXACT Sciences Corporation (NASDAQ: EXAS) reportedly approached Invitae Corp (NYSE: NVTA) for a potential merger. These are the details.

Report: Exact Sciences (EXAS) Approached Invitae (NVTA) For Merger Offer

MercadoLibre

Roku

Shopify

Block

Teladoc

Tesla

Twilio

Zillow

Trimble

The haters have come out against portfolio manager Cathie Wood. In fact, an ETF is preparing to launch that bets against her stocks to buy.

10 Stocks to Buy From Cathie Wood's Fleet of ETFs

Exact Sciences' (EXAS) legacy Screening business sees significant improvement in revenues during the second quarter on Cologuard volume growth.

Exact Sciences (EXAS) Q2 Loss Wider Than Expected, Revenues Top

Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q2 2021 Results - Earnings Call Transcript

Shares of Exact Sciences (NASDAQ:EXAS) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 77.59% over the past year to ($1.03), which missed the estimate of ($0.76).

Exact Sciences: Q2 Earnings Insights

MADISON, Wis., July 28, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $434.8 million for the second quarter ended June 30, 2021, compared to $268.9 million for the same period of 2020.

Exact Sciences Announces Second Quarter 2021 Results

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Should You Buy?

EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year

Bull of the Day: Exact Sciences (EXAS)

MADISON, Wis., July 8, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its second quarter 2021 financial results after the close of the U.S. financial markets on July 28, 2021.

Exact Sciences schedules second quarter 2021 earnings call

Up around 2.5x from its low in March 2020, at the current price of $126 per share, we believe EXACT Sciences Corporation stock has further upside potential. EXAS, a molecular diagnostics company, has seen its stock rise from $51 to $126 off its March 2020 low, much more than the S&P which increased.

Strong Revenue Trend Could Drive EXACT Sciences Corporation Stock To $160

Aclaris Therapeutics

ADC Therapeutics

Allegheny Technologies

AvroBio Inc

Campbell Soup

Crane Company

Cemex SAB de CV

Tuesday's futures were fairly positive after a somewhat mixed start to the week.

Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

Exact Sciences (EXAS) Down 1.4% Since Last Earnings Report: Can It Rebound?

Modeling data exhibits efficacy of Exact Sciences' (EXAS) Cologuard compared to FIT and other colorectal cancer diagnostic options.

Exact Sciences (EXAS) Reveals Promising Data on Cologuard

CRISPR Therapeutics

Twist Bioscience Corp

They're well below peak levels set earlier this year. But they could be huge winners over the long run.

4 Unstoppable Healthcare Stocks to Buy on the Dip

Boston Scientific

Molson Coors Brewing

Autodesk

Allied Esports Entertainment Inc

Gap Inc

Constellation Brands

Stryker

With the trading day more than halfway over, the markets had dipped after a relatively strong start to the day.

Boston Scientific, Gap, Molson Coors and More Tuesday Afternoon Analyst Calls

MADISON, Wis., May 21, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today highlights data from one oral and one poster presentation being featured at the 2021 Digestive Disease Week® (DDW®) virtual annual meeting, taking place May 21-23.

Modeling Data Showed Cologuard® Was Superior to Fecal Immunochemical Test (FIT) on Cost Effectiveness and Colorectal Cancer Incidence and Mortality

Exact Sciences (EXAS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Strength Seen in Exact Sciences (EXAS): Can Its 9.2% Jump Turn into More Strength?

The company's Cologuard DNA test appears to be in good shape to maintain its market leadership.

Why Exact Sciences Stock Soared Today

MADISON, Wis., May 19, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced new data on its cancer tests and treatment guidance tools will be showcased in seven presentations and one e-abstract at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8.

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

DraftKings

PayPal

Buying the stock market weakness? Or staying on the sidelines?

Are You a Glass Half Full or Half Empty Investor?

MADISON, Wis., May 18, 2021 /PRNewswire/ -- The United States Preventive Services Task Force (USPSTF) today released its final colorectal cancer screening recommendation that screening begin at age 45.

Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45

Emerging early cancer diagnostics company with innovative products and the potential to disrupt conventional screening methods. Strong pipeline of future products along with promising growth in recurring revenues.

Exact Sciences: Emerging Leader In Cancer Screening

Despite ongoing pandemic-related headwinds, the medical diagnostic test maker's revenue grew. So how will it perform as those headwinds dissipate?

News for Exact Sciences Stock (EXAS)